Liver surgery/pharmacological preconditioning Surgery Liver surgery
Conditions
Interventions
There will be three arms to the study. Participants will be randomised to:
Arm A: this is the control group, which will receive an infusion of saline over one hour into a peripheral vein
Arm B: this g
Sponsors
University of Edinburgh (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients scheduled to undergo major hepatic resection (three or more segments) 2. Aged between 18 and 80 years, either sex
Exclusion criteria
Exclusion criteria: 1. Patients undergoing minor resections (less than three segments) 2. Jaundiced patients (bilirubin greater than 100 µmol/l) 3. Patients with established cirrhosis 4. Patients who have had a previous liver resection 5. Patients who are unable to give informed consent 6. Patients who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heme oxygenase-1 induction will be measured in the resected liver specimen, and also in peripheral blood cells. HO-1 levels will be assessed by laboratory mesasurement of HO-1 messenger ribonucleic acid (mRNA) and protein level (real-time polymerase chain reaction [PCR] and Western blotting respectively) and HO enzymatic activity. HO-1 will be localised in the liver by immunohistochemistry of the liver tissue. Total body production of carbon monoxide (CO, a product of HO-1 activity) will be measured by CO levels in exhaled air and by blood levels of carboxy-haemoglobin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function on each day during the hospital stay will be assessed by clinical and biochemical means. Clnical evidence of encephalopathy and clinical progress will be measured. Serum levels of alanin aminotransferase (ALT), prothrombin time (PT), lactate and bilirubin will be measured biochemically. Hepatic clearance of indocyanine green will be measured. | — |
Countries
United Kingdom
Outcome results
None listed